anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1,171,195. Artificial teeth. DENTISTS' SUPPLY CO. OF NEW YORK. 26 June, 1967 [27 June, 1966], No. 20468/67. Heading A5R. [Also in Division C3] A composite artificial tooth comprises a synthetic resin portion which includes at least a part of the base surface 6 and the adjacent wall surfaces 8, and a dental ceramic portion 4, the synthetic resin portion allowing ease of bonding to a synthetic resin denture base, the synthetic resin portion being integrally connected to the ceramic portion by a silane chemical bonding agent. The resin portion and the ceramic portion may be also held together by undercut keying formations (Figures 10- 13, not shown) in addition to the silane bonding composition. Synthetic resins suitable to comprise the first portion are exemplified and include polymerized acrylates, methacrylates, and vinyls, polycarbonates, and epoxy resins, and autocuring plastics. The dental ceramic may comprise porcelain and the silane bonding compositions is exemplified. Methods for preparing artificial teeth are described and include forming a porcelain veneer, adding a porcelain backing, exposing the tooth to boiling water, applying the bonding agent, and adding the portion of synthetic resin.
The rapidly evolving field of immunometabolism explores how changes in local immune environments may affect key metabolic and cellular processes, including that of adipose tissue. Importantly, these changes may contribute to low-grade systemic inflammation. In turn, chronic low-grade inflammation affecting adipose tissue may exacerbate the outcome of metabolic diseases. Novel advances in our understanding of immunometabolic processes may critically lead to interventions to reduce disease severity and progression. An important example in this regard relates to obesity, which has a multifaceted effect on immunity, activating the proinflammatory pathways such as the inflammasome and disrupting cellular homeostasis. This multifaceted effect of obesity can be investigated through study of downstream conditions using cellular and systemic investigative techniques. To further explore this field, the National Institutes of Health P30 Nutrition Obesity Research Center at Harvard, in partnership with Harvard Medical School, assembled experts to present at its 24th Annual Symposium entitled "Adiposity, Immunity, and Inflammation: Interrelationships in Health and Disease" on 7 June, 2023. This manuscript seeks to synthesize and present key findings from the symposium, highlighting new research and novel disease-specific advances in the field. Better understanding the interaction between metabolism and immunity offers promising preventative and treatment therapies for obesity-related immunometabolic diseases.
Participants in the LLS Program and Usual Care condition will receive LLS services such as information, services, and financial aid so that patients can have better access to healthcare and better quality of life. Participants will also receive the standard care. Participants will be in this group for 6 months.
PURPOSE: A composition containing therapeutic agents and/or breath freshening agents for use in the oral cavity is provided. CONSTITUTION: A mucoadhesive film contains as essential components a water-soluble polymer or a combination of water-soluble polymers, one or more plasticizers or surfactants, one or more polyalcohols, and a pharmaceutically or cosmetically active ingredient. The polymers used for the mucoadhesive film include polymers which are hydrophilic and/or water-dispersible. Preferred polymers are water-soluble cellulose-derivatives. Hydroxypropylmethyl cellulose, hydroxyethyl cellulose, or hydroxypropyl cellulose, either alone, or mixtures thereof, are particularly preferred. The concentration of the water-soluble polymer in the final film can vary between 20 and 75% (w/w), preferably between 50 and 75% (w/w). The surfactants used for the mucoadhesive film may be one or more nonionic surfactants. When a combination of surfactants is used, the first component may be a polyoxyethylene sorbitan fatty acid ester or a.alpha.-hydro-.omega.-hydroxypoly (oxyethylene)poly(oxypropylene)poly(oxyethylene) block copolymer, while the second component may be a polyoxyethylene alkyl ether or a polyoxyethylene castor oil derivative.
FIELD: medicine, ophthalmology, pharmacy. SUBSTANCE: for ophthalmiatrics invention proposes to use fraction of polysaccharides of the general formula (C 6 H 12 O 6 ) 3-20 , from callus tissue of plants of Ungernia species containing 0.1-20% of potassium of polysaccharide weight. Preparation is used by oral route in the daily dose 10 -6 -10 -3  of active component per 10 kg of body weight for 7-30 days as ophthalmic drops (2-3 drops of extract per tea spoon of water) or as lotions, or in combination using different forms of administration. Agent provides high effectiveness and safety in treatment. EFFECT: enhanced effectiveness of agent, valuable medicinal properties. 4 cl, 1 tbl, 4 ex
BACKGROUND: Low mobility of patients during hospitalisation is associated with adverse outcomes. To successfully change behaviours related to mobility of older hospitalised patients, we need to better understand the mechanisms underlying patient and healthcare professional behaviours. In this study, we thus assessed patient- and healthcare professional-reported intentions and behaviours related to mobility of older patients hospitalised on an acute medical ward, based on a theoretical framework - the Health Action Process Approach (HAPA) model - and on additional barriers and facilitators to mobility.
METHODS: We conducted a cross-sectional survey in April 2022 among patients aged ≥60 years recently hospitalised on an an acute medical ward of one of three hospitals of different language/cultural regions of Switzerland, and healthcare professionals (physicians, nurses/nursing assistants, physiotherapists) working on those wards. The survey assessed the HAPA model and additional barriers and facilitators to patient mobility at hospital, as previously identified in the literature. The target behaviour studied was "to move as much as possible during hospitalisation" for patients and "to ensure my patients move as much as possible during hospitalisation" for healthcare professionals. We conducted hierarchical linear regressions to determine factors associated with the self-reported intention to perform the behaviour and with the self-reported behaviour itself.
RESULTS: A total of 142 healthcare professionals (61 physicians, 59 nurses, 22 physiotherapists) and 200 patients (mean age 74 years) completed the survey. Patients with higher intention to move as much as possible during hospitalisation scored significantly higher on factual knowledge, outcome expectancies and risk perception. Healthcare professionals with higher intention to ensure that their patients move as much as possible during hospitalisation scored higher on action knowledge, outcome expectancies and risk perception. The more the patients reported that they moved as much as possible during hospitalisation, the higher their action knowledge and action control. The more healthcare professionals reported that they ensure that patients move as much as possible during hospitalisation, the higher they scored on factual knowledge, role perception, planning and action control.
CONCLUSIONS: factual and action knowledge, self-efficacy, outcome expectancies, risk perception, planning and action control were identified as important drivers of patient- and healthcare professional-reported intentions and behaviours related to inpatient mobility. These parameters can be addressed through behaviour-change interventions and should be considered in future interventions to successfully implement practice changes, with the goal of improving mobility of older patients during hospitalisation, and thus the outcomes of this particularly vulnerable population.
PROBLEM TO BE SOLVED: To produce a composite powder for cosmetics excellent in feeling in use such as adhesivity and slippage and UV screening activity by treating the surface of fine particles in a state where they are homogeneously and finely dispersed. SOLUTION: A mixture is prepared from 100 pts.wt. fine particles, 0.1-50 pts.wt. surface treating agent and 50-5000 pts.wt. solvent. The mixture is subjected to a surface treating process by using a sand grinder mill as a surface treating apparatus where the mixture is pulverized in wet to finely disperse the aggregation of the particles, and their surfaces are treated with the surface treating agent in this state. Subsequently, they are mixed with inorganic flakes to obtain a composite powder. The compounding ratio of the fine particles to the inorganic flakes is 5:95 to 75:25 in weight ratio. Titanium oxide, zinc oxide, etc., of 0.001-0.1μm in particle diameter is used as the fine particles, methylhydrogenpolysiloxane, etc., is used as the surface treating agent, and synthetic flakes, etc., mainly containing titanium oxide, etc., are used as the inorganic flakes.  In the composite powder, aggregated fine particles are dissociated into fine particles and fixed on the inorganic flakes in a dispersed state, and therefor the particles do not reaggregate during the handling after the surface treatment and exhibit excellent ultraviolet screening activity.
BACKGROUND: Childhood and adolescent obesity pose significant challenges to global health, with escalating prevalence and associated short- and long-term health consequences. This longitudinal study leveraged data from the Tehran Lipid and Glucose Study (TLGS) to investigate the trends of obesity among Tehranian children and adolescents over a 21-year period.
METHODS: Utilizing data from TLGS phases I to VII (1999-2021), we included 3845 participants aged 3-18 years at the beginning of phase I. Anthropometric measures, including height and weight, were collected, and body mass index (BMI) was calculated. Childhood obesity (2-19 years) was defined as BMI-for-age > 2SD based on World Health Organization (WHO) standards, and adult obesity was defined as BMI ≥ 30. Descriptive statistics, trend analysis, prevalence calculations, odds ratios, and interaction analyses were employed for data interpretation.
RESULTS: The mean BMI increased from 18.46 ± 4.37 kg/m² at Phase I to 26.36 ± 5.03 kg/m² at Phase VII. Boys exhibited a greater increase in BMI than girls, and age at study entry influenced BMI trajectories. The prevalence of obesity rose from 6.4% at Phase I to 21.5% at Phase VII, with a more pronounced increase in boys. Odds ratios for obesity steadily increased across phases, indicating a growing risk. Interaction analyses revealed age-specific dynamics, with older participants demonstrating lower odds ratios initially but higher odds ratios in later phases.
CONCLUSION: Our study shows a worrisome increase in childhood obesity among Tehranian children and adolescents over 21 years. Sex- and age-specific trends emphasize the necessity for targeted interventions, informing policymakers, healthcare practitioners, and educators regarding public health strategies and interventions against the obesity epidemic.
This experiment aimed to determine the effect of adaptive duration to saline water on behaviors, weight gain and blood biochemical parameters in growing goats. The experiment was arranged in a completely randomized design, which included four treatments with five animals per group. The goats were administered either fresh water (control) or seawater with a salinity of 1.5%, with varying durations of adaptation to seawater. The adaptive durations included an abrupt change (A0) from fresh water to seawater with a salinity of 1.5% or stepwise adaptation either 4 (A4) or 7 (A7) days of increasing saline concentrations. The results showed that dry matter intake in the non-adapted goats (A0 group) was lower than that of the control group or the adapted goats throughout the experiment (p<0.05). In contrast, water intake from drinking saline water was greater than that in the control group (p<0.05). Body weigh did not differ among the treatments; however, non-adapted goats exhibited a lower weight gain than the adapted goats (p<0.05). The goats in the A0 and A4 groups exhibited increased plasma levels of urea, AST, and ALT compared with the control and A7 groups. However, blood electrolyte levels remained unchanged and were within the normal range for goats. Therefore, it is concluded that the stepwise adaptation to seawater with a salinity of 1.5% for 21 days has no influence on productivity and health status of goats.
A pharmaceutical composition having an analgesic, anaesthetic and antiseptic action, a method for producing the pharmaceutical composition and a method for treatment of otitis and other ear injuries. The group of inventions relates to medicine and can be used in the treatment of otitis and other ear injuries. The invention relates to a pharmaceutical composition in the form of ear drops, containing 4 wt. % phenazone or propyphenazone, 2 wt. % articaine and 0.05-0.2 wt. % benzalkonium chloride.
The invention provides a benzo five-membered unsaturated heterocycle compound and a preparation method thereof. The compound has the structure shown in the general formula (I). A test shows that the compound has the activity for up regulating the bone morphogenetic protein BMP-2 expression and the function of resisting osteoporosis. The invention also provides a medicine composition containing the compound as the active ingredient. An in-vitro activity test shows that the compound represents obvious up-regulating function for the bone morphogenetic protein BMP-2 expression; and an SAMP6 rapid ageing mice in-vivo activity test result shows that the compound has the function of improving the osteoporosis of ageing model mice. The invention provides a basis for further research and development of the osteoporosis-resisting medicine of the compound.
The invention relates to the field of a traditional Chinese medicine, and particularly relates to a drug for repairing a skin injury and a preparation method of the drug. The drug comprises a topical agent prepared from the following components in parts by weight: 20-25 parts of egg yolk oil, 15-25 parts of tetrastigma hemsleyanum, 15-20 parts of angelica oil, 10-15 parts of lavender essential oil and 25-40 parts of sesame oil. The drug for repairing the skin injury has good treatment effects on various degrees of skin injuries, and especially has a unique curative effect on deep second skin trauma. The curative effect is mainly reflected as follows: the skin injury can be cured by direct external application, does not need skin grafting, and is short in treatment cycle. The clinical test proves that the deep second skin trauma can be cured after 2-3 weeks when being treated by using the drug for repairing the skin injury. Compared with the traditional skin grafting, the treatment course is shortened by at least 10-30 days, and the drug can be used for stopping pain, resisting bacteria and diminishing inflammation, protecting the wound from being polluted, promoting wound healing, and carrying out reducing repairing on the skin, and is safe and free of a side effect.
Sham TENS will be performed using equipment identical in appearance to active TENS (Neurodyn Portable TENS, Ibramed, Amparo, São Paulo, Brazil) specifically designed for this study. The device will emit an electrical current gradually increased during the first 30 seconds, followed by a gradual decrease over the subsequent 15 seconds reaching an intensity of 0 mA. The device will remain inactive during the rest of the application, but will have a flashing light, giving the patient the appearance that it is active. The assessor will inform the patient that it is possible to feel the sensation of the current or not depending on individual characteristics. This type of equipment is validated and has been used in other studies to facilitate the blinding of participants. Both systems will be calibrated using a digital oscilloscope (DPO 7000, Tektronix Inc., Beaverton, OR, USA).
In the first part of the study, cohorts of 3 patients receive sodium selenite iv, starting with a dose of 0.5 mg/m2. If no serious adverse event the next cohort is treated according to a dose escalation schedule and this part has been completed. In the modified protocol, a continuous infusion over 2 days will be administered.
PURPOSE:To provide an adhesive useful for dental treatment which consists mainly of a copolymer of a vinyl compd. with a specified carboxylic anhydride group and a copolymerizable vinyl compd. and has strong adhesion directly to dentine without the need of pretreatment with an aqueous phosphoric acid solution. CONSTITUTION:The adhesive consists of a (a) a copolymer of a vinyl compd. containing 40-90mol% copolymerizable vinyl compd. with a hydrophobic group and having a carboxylic anhydride group which may have the carboxylic acid group linked to vicinal carbon atoms, (b) a copolymerizable vinyl compd. and, when necessary, (c) an organic titanate. When the vinyl compd. content in (a) exceeds 90mol%, no sufficient adhesion to dentine is obtaonable, while when it is less than 40mol%, commercial production is made difficult and the adhesive tends to have insufficient water resistance.
PURPOSE: The impact of perineal descent (PD) on functional outcome and quality of life after ventral mesh rectopexy (VMR) is unknown. The purpose of this study was to analyze the effect of PD on the functional outcome and quality of life (QOL) after VMR.
METHODS: A retrospective analysis was performed on fifty-five patients who underwent robotic VMR between 2018 and 2021. Pre and postoperative data along with radiological studies were gathered from a prospectively maintained database. The Cleveland Clinic Constipation score (CCCS), the Rome IV criteria and the 36-Item Short-Form Health Survey (SF-36), were used to measure functional results and QOL.
RESULTS: All 55 patients (mean age 57.8 years) were female. Most patients had radiological findings of severe PD (n = 31) as opposed to mild/moderate PD (n = 24). CCCS significantly improved at 3 months and 1 year post-VMR (mean difference = -4.4 and -5.4 respectively, p < 0.001) with no significant difference between the two groups. The percentage of functional constipation Rome IV criteria only showed an improved outcome at 3 months for severe PD and at 1 year for mild/moderate PD (difference = -58.1% and -54.2% respectively, p < 0.05). Only the SF-36 subscale bodily pain significantly improved in the mild/moderate PD group (mean difference = 16.7, p = 0.002) 3 months post-VMR which subsided after one year (mean difference = 5.5, p = 0.068).
CONCLUSION: Severe PD may impact the functional outcome of constipation without an evident effect on QOL after VMR. The results, however, remain inconclusive and further research is warranted.
AIMS: This study aimed to provide up-to-date information on paediatric population pharmacokinetic models of tacrolimus and to identify factors influencing tacrolimus pharmacokinetic variability.
METHODS: Systematic searches in the Web of Science, PubMed, Scopus, Science Direct, Cochrane, EMBASE databases and reference lists of articles were conducted from inception to March 2023. All population pharmacokinetic studies of tacrolimus using nonlinear mixed-effect modelling in paediatric solid organ transplant patients were included.
RESULTS: Of the 21 studies reviewed, 62% developed from liver transplant recipients and 33% from kidney transplant recipients. Most studies used a 1-compartment model to describe tacrolimus pharmacokinetics. Body weight was a significant predictor for tacrolimus volume of distribution (Vd/F). The estimated Vd/F for 1-compartment models ranged from 20 to 1890 L, whereas the peripheral volume of distribution (Vp/F) for 2-compartment models was between 290 and 1520 L. Body weight, days post-transplant, CYP3A5 genotype or haematocrit were frequently reported as significant predictors of tacrolimus clearance. The estimated apparent clearance values range between 0.12 and 2.18 L/h/kg, with inter-individual variability from 13.5 to 110.0%. Only 29% of the studies assessed the generalizability of the models with external validation.
CONCLUSION: This review highlights the potential factors, modelling approaches and validation methods that impact tacrolimus pharmacokinetics in a paediatric population. The clinician could predict tacrolimus clearance based on body weight, CYP3A5 genotype, days post-transplant or haematocrit. Further research is required to determine the relationship between pharmacogenetics and tacrolimus pharmacodynamics in paediatric patients and confirm the applicability of nonlinear kinetics in this population.
Group A: Fifteen (20) patients will be treated with Allogenic human mesenchymal stem cells (Allo-hMSCs): A concentration of 5 million cells/ml delivered in a dose of 2.5 x 10\^5 cells per kg of recipient (5 million/20kg) Allo-hMSCs. The entire dose of the cells will be divided and delivered in 6-10 open intramyocardial injections during the BDCPA operation.
Participants received matching placebo once daily plus best supportive care (BSC) during the blinded period. Participants were allowed to crossover to treatment with everolimus 10mg once daily plus BSC during the open-label period.
The invention comprises N-butyryl-, N-benzoyl- and N-palmitoyl-glutamines and N-butyryl-, N-palmitoyl- and N-diphenylacetylasparagines.  These compounds, and other N-acyl-glutamines and asparagines such as the N-formyl, N-acetyl, N-propionyl, N-valeryl, N-isobutyryl, N-phenylacetyl, N-trimethylacetyl, N-stearoyl and N-sulphonyl compounds, may be prepared by reacting glutamine or asparagine with an acylating agent such as an acyl halide or acid anhydride, conveniently in a liquid reaction medium at 0 DEG  C. under substantially neutral conditions, such conditions being conveniently achieved by first neutralizing the glutamine or asparagine with a base e.g. aqueous sodium hydroxide, and then adding, simultaneously, a solution of the acylating agent and a solution of a base.  Salts of the N-acylated glutamines and asparagines may be prepared by conventional methods.  Examples describe the preparation of the L-forms of the compounds of the invention and also the preparation of N-acetyl - L - glutamine, N - p - toluenesulphonyl-L - glutamine, N - acetyl - L - asparagine and N-phenylacetyl-L-asparagine.ALSO:An anticonvulsant composition comprises at least one compound selected from N-acyl derivatives of glutamine and of asparagine and salts of such derivatives and a solid pharmaceutical carrier, or a sterile liquid suitable for parenteral injection or an orally administrable oil.  A liquid carrier may be accompanied by a solubilizer and/or dispersing agent, a liquid composition may be contained in a capsule and a solid composition may be in the form of a tablet or powder and may contain flavouring and disintegrating agents.  Suitable solid carriers include corn starch, sugar, talc, and magnesium carbonate, and suitable oils include olive oil and sesame oil.  Preferably the N-acyl group has 20 carbon atoms or less and is derived from a monocarboxylic acid, but it may be, for example, an N-sulphonyl group.  Compositions in unit dosage form may contain from 500 mg. to 75 g. of active ingredient.  A composition containing benzoyl-L-asparagine, veegum H.V., glycerine, methyl p-hydroxybenzoate, propyl p-hydroxybenzoate and water is described.